O'Kelly M - Search Results

1

Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials.

Matcham J, Julious S, Pyke S, O'Kelly M, Todd S, Seldrup J, Day S. Matcham J, et al. Pharm Stat. 2011 Jan-Feb;10(1):70-3. doi: 10.1002/pst.417. Pharm Stat. 2011. PMID: 20187020

2

Making available information from studies sponsored by the pharmaceutical industry: some current practices.

O'Kelly M, Julious SA, Pyke S, Day S, Todd S, Seldrup J, Matcham J. O'Kelly M, et al. Pharm Stat. 2011 Jan-Feb;10(1):60-9. doi: 10.1002/pst.430. Pharm Stat. 2011. PMID: 21275036

3

The potential for bias in reporting of industry-sponsored clinical trials.

Pyke S, Julious SA, Day S, O'Kelly M, Todd S, Matcham J, Seldrup J. Pyke S, et al. Pharm Stat. 2011 Jan-Feb;10(1):74-9. doi: 10.1002/pst.429. Pharm Stat. 2011. PMID: 21275037

4

Estimands: discussion points from the PSI estimands and sensitivity expert group.

Phillips A, Abellan-Andres J, Soren A, Bretz F, Fletcher C, France L, Garrett A, Harris R, Kjaer M, Keene O, Morgan D, O'Kelly M, Roger J. Phillips A, et al. Pharm Stat. 2017 Jan;16(1):6-11. doi: 10.1002/pst.1745. Epub 2016 Mar 21. Pharm Stat. 2017. PMID: 26997517

5

Proposed best practice for projects that involve modelling and simulation.

O'Kelly M, Anisimov V, Campbell C, Hamilton S. O'Kelly M, et al. Pharm Stat. 2017 Mar;16(2):107-113. doi: 10.1002/pst.1789. Epub 2016 Nov 3. Pharm Stat. 2017. PMID: 27809406 Free article.

6

Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models.

Ratitch B, O'Kelly M, Tosiello R. Ratitch B, et al. Pharm Stat. 2013 Nov-Dec;12(6):337-47. doi: 10.1002/pst.1549. Epub 2013 Jan 4. Pharm Stat. 2013. PMID: 23292975

7

Sensitivity to censored-at-random assumption in the analysis of time-to-event endpoints.

Lipkovich I, Ratitch B, O'Kelly M. Lipkovich I, et al. Pharm Stat. 2016 May;15(3):216-29. doi: 10.1002/pst.1738. Epub 2016 Mar 21. Pharm Stat. 2016. PMID: 26997353

8

Life Cycle Modeling and Simulation: Current Practice and Future Impact on Health Care Innovation and Delivery.

O'Kelly M, Berry S, Walp D, Garrett A. O'Kelly M, et al. Ther Innov Regul Sci. 2013 Mar;47(2):175-182. doi: 10.1177/2168479012471831. Ther Innov Regul Sci. 2013. PMID: 30227526

9

Recent Developments in the Prevention and Treatment of Missing Data.

Mallinckrodt C, Roger J, Chuang-Stein C, Molenberghs G, O'Kelly M, Ratitch B, Janssens M, Bunouf P. Mallinckrodt C, et al. Ther Innov Regul Sci. 2014 Jan;48(1):68-80. doi: 10.1177/2168479013501310. Ther Innov Regul Sci. 2014. PMID: 30231419

10

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.

Ratitch B, Bell J, Mallinckrodt C, Bartlett JW, Goel N, Molenberghs G, O'Kelly M, Singh P, Lipkovich I. Ratitch B, et al. Among authors: o kelly m. Ther Innov Regul Sci. 2020 Mar;54(2):324-341. doi: 10.1007/s43441-019-00061-x. Epub 2020 Jan 4. Ther Innov Regul Sci. 2020. PMID: 32072573

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters